AI Summary
5 min read🎙️ The Voices & The Context
- The Format: Structured interview with a tech investor host probing a pharma CEO on strategy, innovation, and industry trends.
- The Key Players:
- Guest: Vasant Narasimhan (Voss), CEO of Novartis since 2018; physician-scientist who transformed a 250-year-old conglomerate into a focused biotech powerhouse, unlocking $180B in value.
- Host: Jorge Conde, A16Z General Partner with Peruvian roots, drawing personal connections and sharp questions on biotech investing.
- The Vibe: Educational and optimistic, blending CEO war stories with cutting-edge science; inspiring for biotech enthusiasts.
🗝️ Key Themes & Topics
Four core pillars emerge: corporate reinvention, breakthrough platforms, AI acceleration, and global challenges.
- Topic 1: Pure-Play Transformation. Narasimhan details spinning off consumer health (GSK JV), Alcon, and Sandoz, shedding non-core businesses to focus on biopharma in oncology, immunology, neuroscience, and cardiorenal—unlocking $180 billion in value despite misallocated capital and execution hurdles.
- Topic 2: Platform Technologies. Deep dive into cell/gene therapies (e.g., immunology resets), RNA medicines (siRNA for cholesterol, eyeing yearly dosing), and radioligand therapies (radioactive particles targeting cancers like PSMA in prostate, scaling complex supply
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
What you'll learn
- 1 (00:00) **🎙️ Introduction: Vasant Narasimhan**
- 2 (02:17) **Novartis Overview and Vasant's Background**
- 3 (04:09) **Transformation to Pure-Play Medicines Company**
- 4 (09:00) **Core Focus: Disease Areas and Platform Technologies**
- 5 (10:21) **Cell and Gene Therapies**
- 6 (14:54) **RNA Medicines**
- 7 (20:24) **Radioligand Therapies**
+ Full timestamped outline available in the app
Show Notes
a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal.
Resources:
Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhan
Follow Jorge Conde on X: https://x.com/JorgeCondeBio
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More from this podcast
a16z Show →